NASDAQ:AIXC

Qualigen Therapeutics Q4 2025 Earnings Report

Qualigen Therapeutics logo
$1.08 +0.03 (+3.24%)
Closing price 06/26/2026 03:57 PM Eastern
Extended Trading
$1.07 -0.01 (-1.29%)
As of 06/26/2026 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Qualigen Therapeutics EPS Results

Actual EPS
-$3.76
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Qualigen Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Qualigen Therapeutics Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Qualigen Therapeutics Earnings Headlines

AIXC AIxCrypto Holdings, Inc.
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
See More Qualigen Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Qualigen Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Qualigen Therapeutics and other key companies, straight to your email.

About Qualigen Therapeutics

Qualigen Therapeutics (NASDAQ:AIXC), a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

View Qualigen Therapeutics Profile